The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Siddhesh Nayak & PACs
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.5 pts more than Nifty Microcap 250 and 9.5 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Siddhesh Anant Nayak, part of the promoter group of Clinitech Laboratory Ltd, purchased 1,200 equity shares in the open market on March 27, 2026. This was disclosed under Regulation 29(2) of SEBI's Takeover Regulations along with six Persons Acting in Concert (PACs). After the acquisition, the combined promoter group holding rose to 14,65,400 shares, i.e., 64.20% of the company's total share capital (up marginally from 64.15%). The total equity share capital of the company remains unchanged at 22,82,400 shares. The purchase is a small open-market increase by an existing promoter, not a fresh acquisition from the public.
This is a very small (0.05%) open-market purchase by the promoter group and is unlikely to have any material impact on the stock price. It signals continued promoter confidence but does not change control of the company, as promoter holding was already above 64%.